Loading...
•
Mar 31, 2024
Mink Therapeutics Q1 2024 Earnings Report
Reported first quarter 2024 results, highlighted by clinical program updates and financial results.
Key Takeaways
MiNK Therapeutics reported a net loss of $3.8 million, or $0.11 per share, for the first quarter of 2024. The company's cash balance at the end of the quarter was $5.8 million and cash used in operations was $2.5 million.
Made significant strides across iNKT cell programs.
Focused on generating clinical data from lead program, agenT-797.
Strengthened financial position with a $5.8 million capital infusion.
Advancing innovative next-generation therapies, including MiNK-215.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...